Table 1 Characteristics of virological responses by group of treatment and genotypes in treated HIV/HCV co‐infected patients.
| IFN group | PEG‐IFN group | Total | p Value | |
|---|---|---|---|---|
| Number of patients, n (%) | 164 (50.8) | 159 (49.2) | 323 | |
| Viral load (log IU/ml) | 5.87±0.70 | 5.88±0.71 | 5.87±0.70 | 0.95 |
| More than 80% of doses, n (%)† | 107 (65.2) | 102 (64.2) | 209 (64.7) | 0.75 |
| Sustained responders, n (%) | 39 (23.8) | 49 (30.8) | 88 (27.2) | 0.041 |
| Responders with relapse, n (%) | 8 (4.9) | 18 (11.3) | 26 (8.1) | 0.032 |
| Responders with breakthrough, n (%) | 14 (8.5) | 13 (8.2) | 27 (8.4) | 0.85 |
| Non‐responders, n (%) | 103 (62.8) | 79 (49.7) | 182 (56.7) | 0.075 |
| Genotype 1 or 4, n (%) | 100 (61.0) | 98 (61.6) | 198 (61.3) | 0.91 |
| Sustained response for genotype 1 or 4, n (%) | 7 (7.2) | 19 (19.4) | 26 (13.3) | 0.007 |
| Sustained response for genotype 2 or 3, n (%) | 30 (48.4) | 30 (49.2) | 60 (48.8) | 1.00 |
*p value for comparison of both arms of treatment (not significant if p>0.05); †percentage of patients receiving more than 80% of their treatment with IFN α2b plus ribavirin or PEG‐IFN α2b plus ribavirin.